Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy
- 1 July 2017
- journal article
- review article
- Published by Elsevier in Trends in Cancer
- Vol. 3 (7) , 529-541
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticleProceedings of the National Academy of Sciences, 2013
- Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancerCancer Chemotherapy and Pharmacology, 2013
- Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxiaProceedings of the National Academy of Sciences, 2012
- RETRACTED ARTICLE: HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungsOncogene, 2011
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effectsAngiogenesis, 2011
- The Tumor Microenvironment in Non–Small-Cell Lung CancerSeminars in Radiation Oncology, 2010
- RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularizationProceedings of the National Academy of Sciences, 2009
- RETRACTED: Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cellsProceedings of the National Academy of Sciences, 2009
- Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growthProceedings of the National Academy of Sciences, 2008